Anticancer Activity of Novel Trifluoromethylquinoline Derivatives Designed to Target the Tubulin Colchicine Binding Site
Chemistry & Biodiversity · 2026-06 · 23 (6)
DOI: 10.1002/cbdv.71420 ↗At a glance
Journal article in Chemistry & Biodiversity, published online on 2026-06-15. Written by Xiangkai Kong and 4 co-authors. Institution: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine & School of Pharmaceutical Sciences, Guizh…. Major MEDLINE topics: Antineoplastic Agents, Tubulin, Colchicine, Tubulin Modulators. Cited 1 times so far (Crossref); 30 references. Funded by: National Natural Science Foundation of China, Guizhou Provincial Major Scientific and Technological Program, High-level Innovative Talents Fund of Guizhou Province.
Abstract (original language)
Colchicine binding site inhibitors (CBSIs) have developed rapidly in recent years as antitumor agents. Currently, no inhibitors of this specific class are approved for clinical use. In this study, a series of novel 2‐trifluoromethyl‐4‐aminoquinoline derivatives were designed, synthesized, and evaluated for their antiproliferative activity. Among them, compound 8a was the most potent against LNCaP cells with an IC 50 value of 1 nM. Mechanistic studies demonstrated that 8a disrupted tubulin polymerization by binding to the colchicine site of tubulin. Meanwhile, 8a could induce cell apoptosis. Molecular docking indicated that 8a could bind well to the amino acid residues in microtubule protein cavities. Overall, these findings suggested that compound 8a could be a promising antitumor agent targeting the tubulin colchicine binding site.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine & School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China.
- Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guiyang, P.R. China.
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Natural Products Research Center of Guizhou Province, Guizhou Medical Univer…
Funding
- National Natural Science Foundation of China
- Guizhou Provincial Major Scientific and Technological Program
- High-level Innovative Talents Fund of Guizhou Province
- Department of Science and Technology of Guizhou Province
- the Project of Health Commission of Guizhou Province
- Guizhou Medical University
- Guizhou Provincial Education Department Youth Science and Technology Talent Development Project
- Guizhou Provincial Science and Technology Department
Cite
APA
Kong, X., Su, Y., He, S., Tang, L., & Meng, X. (2026). Anticancer Activity of Novel Trifluoromethylquinoline Derivatives Designed to Target the Tubulin Colchicine Binding Site. Chemistry & Biodiversity, 23(6). https://doi.org/10.1002/cbdv.71420
Vancouver
Kong X, Su Y, He S, Tang L, Meng X. Anticancer Activity of Novel Trifluoromethylquinoline Derivatives Designed to Target the Tubulin Colchicine Binding Site. Chemistry & Biodiversity. 2026;23(6). doi:10.1002/cbdv.71420
BibTeX
@article{Kong2026,
author = {Kong, Xiangkai and Su, Yu and He, Siyu and Tang, Lei and Meng, Xueling},
title = {Anticancer Activity of Novel Trifluoromethylquinoline Derivatives Designed to Target the Tubulin Colchicine Binding Site},
journal = {Chemistry & Biodiversity},
year = {2026},
volume = {23},
number = {6},
doi = {10.1002/cbdv.71420}
}
EUVIMED